Literature DB >> 15300886

Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies.

Chung-Pin Li1, Tze-Sing Huang, Yee Chao, Full-Young Chang, Jacquline Whang-Peng, Shou-Dong Lee.   

Abstract

AIM: To evaluate the diagnostic value of assaying telomerase activity in ascites cells for the differential diagnosis of malignant and non-malignant ascites.
METHODS: Ascites from 40 patients with hepatocellular carcinoma (HCC), 31 with non-HCC gastrointestinal carcinoma (CA), and 24 with liver cirrhosis (LC) were analyzed for telomerase activity. The telomerase activities in cell pellets from ascites were measured according to the Telomeric Repeat Amplification Protocol (TRAP) and quantified with a densitometer.
RESULTS: Positive telomerase activity was detected in 16 of 31 (52%) CA patients, 10 of 40 (25%) HCC patients, and 1 of 24 (4%) LC patients (P<0.001). The telomerase activity was higher in the ascites of CA patients than in the ascites of HCC or LC patients (CA: 22.9 +/- 5.8, HCC: 6.7 +/- 2.5, LC: 1.3 +/- 1.3, P = 0.001). Cytology was positive in 18 CA patients (58%) and 1 HCC patient (2.5%), respectively. The positive telomerase activity was not related to patients' age, gender, and ascitic protein concentration, but to white blood count (r = 0.31, P = 0.002), neutrophil count (r = 0.29, P = 0.005), and the C-reactive protein level (r = 0.29, P = 0.018). When the results of both cytological examination and telomerase assay were considered together, the sensitivity increased to 77% for CA patients, 25% for HCC patients, and 48% for all 71 gastrointestinal cancer patients.
CONCLUSION: Combining cytological examination of ascites with telomerase activity assay significantly improves the differential diagnosis between malignant and non-malignant ascites. Copyright 2004 The WJG Press ISSN

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300886      PMCID: PMC4572143          DOI: 10.3748/wjg.v10.i17.2468

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

Review 1.  Malignant ascites.

Authors:  S L Parsons; S A Watson; R J Steele
Journal:  Br J Surg       Date:  1996-01       Impact factor: 6.939

2.  Cytological diagnosis and telomerase activity of cells in effusions of body cavities.

Authors:  S Toshima; T Arai; Y Yasuda; T Takaya; Y Ito; K Hayakawa; C Shibuya; N Yoshimi; M Shibayama; Y Kashiki
Journal:  Oncol Rep       Date:  1999 Jan-Feb       Impact factor: 3.906

3.  Telomerase activity in human germline and embryonic tissues and cells.

Authors:  W E Wright; M A Piatyszek; W E Rainey; W Byrd; J W Shay
Journal:  Dev Genet       Date:  1996

4.  Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.

Authors:  R Braunschweig; P Yan; I Guilleret; F Delacretaz; F T Bosman; A Mihaescu; J Benhattar
Journal:  Diagn Cytopathol       Date:  2001-03       Impact factor: 1.582

5.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  Effusion cytology of hepatocellular carcinoma.

Authors:  G Falconieri; F Zanconati; I Colautti; S Dudine; D Bonifacio-Gori; L Di Bonito
Journal:  Acta Cytol       Date:  1995 Sep-Oct       Impact factor: 2.319

Review 7.  Telomerase activity in human cancer.

Authors:  J W Shay; W E Wright
Journal:  Curr Opin Oncol       Date:  1996-01       Impact factor: 3.645

8.  Expression and function of interleukin-8 in human hepatocellular carcinoma.

Authors:  J Akiba; H Yano; S Ogasawara; K Higaki; M Kojiro
Journal:  Int J Oncol       Date:  2001-02       Impact factor: 5.650

9.  Ascitic fluid analysis in hepatocellular carcinoma.

Authors:  A Colli; M Cocciolo; C Riva; L Marcassoli; M Pirola; P Di Gregorio; G Buccino
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

10.  Rapid, quantitative nonisotopic assay for telomerase activity in human tumors.

Authors:  S Gelmini; A Caldini; L Becherini; S Capaccioli; M Pazzagli; C Orlando
Journal:  Clin Chem       Date:  1998-10       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.